Shares in MDMA psychotherapy player Emyria (ASX:EMD) jumped 9.4% to 3.5cps on Monday following reports of ‘interim’ success treating patients with PTSD. Eight patients were treated with MDMA – in conjunction with a professional therapist in the room – with all patients demonstrating “substantial improvement in PTSD symptoms,” Emyria reported on Monday. Patients self-reported gains in quality of life which Emyria perceives to prove both the market potential of MDMA in therapeutic contexts, and, that it could work beyond immediate symptom relief – in other words, achieving a durable psychologica…